Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NanoSight Announce New Appointment

Published: Tuesday, June 26, 2012
Last Updated: Tuesday, June 26, 2012
Bookmark and Share
Leading UK scientist, Dr Andrew Shuttleworth, joins NanoSight board as Director of Diagnostic Sciences.

NanoSight announced the appointment of renowned UK scientist and former government advisor, Dr Andrew Shuttleworth, as Director of Diagnostic Sciences.

NanoSight welcomes Dr Andrew Shuttleworth to the board of the company in the capacity of Director of Diagnostic Sciences. Dr Shuttleworth's appointment further strengthens the scientific team. His experience will greatly add to NanoSight's position as the UK's fastest growing Biotechnology company.

Andrew Shuttleworth brings a wealth of scientific knowledge to the rapidly expanding NanoSight organization. Having been awarded degrees in in applied biological sciences and virology, he spent twenty years at Porton Down research establishments involved in both fundamental research in microbiology and immunology, and the application of that research to medical and defense issues; particularly the rapid identification of select biological agents. This led to a leading role in the development of the UK's first practical biological agent detection system, fielded during the Gulf War in 1991, and acted as the scientific liaison on chemical and biological issues with UK and US Forces throughout the Gulf region. Andrew returned to Porton Down where he directed a team of analytical chemists, microbiologists and operational analysts providing chemical and biological risk and threat assessments. He also provided real-time operational advice and support to the Ministry of Defence, the Home Office and other government departments. In 2001, Andrew took up an appointment with the UK Foreign & Commonwealth Office to provide scientific advice and expertise on a diverse range of topics of national interest.

CEO Jeremy Warren says "Our growing involvement in characterization of exosomes and microvesicles has been driven by users. Increasingly we are recognizing major potential in exosome diagnostics, so the fit with Andrew is remarkable. He has followed development of NanoSight's technology since we began and been an advisor to some of our shareholders plus he has a depth of diagnostics experience. This appointment is as obvious as it is attractive for all parties."

Andrew Shuttleworth comments: "The emerging field of exosomes and nanovesicles now looks set to give rise to a fundamental shift in the way in which disease is detected, diagnosed and monitored. Currently, it is a growing research field, which NanoSight is exploiting fully through the provision of increasingly capable research instrumentation. Eventually, multiple biomarkers will be identified for each relevant disease state and this will drive the development of new analytical capabilities. Whilst it is too early to suggest that NanoSight technology will supplant existing capabilities (e.g. ELISA, qPCR), it would be prudent to recognize that NanoSight has the potential to do so – particularly where multiple-parameter tests and quantitative results might be desirable. NanoSight also has the potential to assist in the development of other novel assay systems that might be needed to fully exploit the potential benefits of exosomes and nanovesicles."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Method Development to Estimate the Purity of Vesicle Preparations
Nanoparticle tracking analysis is used to estimate the purity of vesicle preparations at the Cardiff University School of Medicine.
Thursday, February 28, 2013
Landmark Publication Reports Potential of Exosomes as Biomarkers for Early Disease Detection
NanoSight reports the new publication in one of the most cited peer reviewed journals in nanoscience and nanotechnology, NanoMedicine.
Thursday, July 07, 2011
NanoSight announces interactive webinar on January 27th on Exosome Characterization by Nanoparticle Tracking Analysis
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, will host an interactive webinar on the subject of exosome characterization by Nanoparticle Tracking Analysis.
Thursday, January 20, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
Researchers Can Control Genes Involved in Cancer
A new way to control the activity of a protein, that is often upregulated in cancer, has been discovered by Moffitt researchers through monoubiquitination mechanism.
Mitochondrial Role in Metastatic Cancer
Researchers have manipulated proteins, sourced from tumour cells, that are essential for maintaining tumour cells and in doing so, have significantly reduced the ability of cancer cells.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
Scientists Culture Elusive Yellowstone Microbe
ORNL scientists have successfully isolated and cultured a Yellowstone sourced acidic hot-spring based microbe.
Seeing RNA at the Nanoscale
MIT researchers have developed a new way to image proteins and RNA inside neurons of brain tissue.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!